Wilson Disease Drugs Market By Drug Type (Penicillamine, Trientine, Zinc), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global Wilson disease drugs market accounted for $595.17 million in 2021, and is expected to reach $848.19 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.

Wilson disease is a rare inherited disorder that causes copper to accumulate in the liver, brain and other vital organs of human body. most people with Wilson's disease are diagnosed between the ages of 5 and 35, but it can affect younger and older people, as well. Copper plays a key role in the development of healthy nerves, bones, collagen and the skin pigment melanin. It is normally absorbed from food, and excess is excreted through a substance produced in liver (bile). However, in people with Wilson's disease, copper is not eliminated properly and instead accumulates, possibly to a life-threatening level. Wilson's disease is treatable when diagnosed early, and many people with the disorder live normal lives.

Wilson's disease is inherited as an autosomal recessive trait, this indicates that a person must inherit one copy of the defective gene from each parent in order to have the disease. If the person receives only one abnormal gene, he may not become ill himself, but he is a carrier and can pass the gene to children. Untreated Wilson's disease can be fatal. Serious complications include scaring of liver, kidney problems, liver failure, persistent neurological problems, psychological problems, and blood problems. Wilson disease drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine which further facilitate the growth of the market. However, lack of awareness and diagnosis facility associated with Wilson disease treatment and high treatment cost due to complications are expected to impede the market growth. In contrast, high investment by the government for drug development and increase in healthcare expenditure are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the Wilson disease drugs market.

The Wilson disease drugs market is segmented on the basis of drug type, distribution channel and region. Depending on drug type, the market is classified into Penicillamine, Trientine and Zinc. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global Wilson disease drugs market. The key companies profiled in the report include ANI Pharmaceuticals, Inc., APOTEX, Bausch Health Companies Inc., Breckenridge Pharmaceutical, Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, NAVINTA LLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vivet Therapeutics

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wilson disease drugs market analysis from 2021 to 2031 to identify the prevailing wilson disease drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the wilson disease drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global wilson disease drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

Trientine
Zinc
Penicillamine

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Apotex
- ANI Pharmaceuticals Inc
- Teva Pharmaceutical Industries Limited
- Lupin Ltd
- Dr.Reddy's Laboratories Ltd
- Bausch Health Companies Inc.
- Panacea Biotec Ltd
- par pharmaceutical
- navinta llc
- breckenridge pharmaceutical, inc.

Product Code: A15455

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Market dynamics
- 3.4.1.Drivers
- 3.4.2.Restraints
- 3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market

CHAPTER 4: WILSON DISEASE DRUGS MARKET, BY DRUG TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Penicillamine
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
4.3 Trientine
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
4.4 Zinc
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country

CHAPTER 5: WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Retail Pharmacies
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
5.3 Hospital Pharmacies
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
5.4 Online Pharmacies
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country

CHAPTER 6: WILSON DISEASE DRUGS MARKET, BY REGION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Drug Type
- 6.2.3 North America Market size and forecast, by Distribution Channel
- 6.2.4 North America Market size and forecast, by country
  - 6.2.4.1 U.S.
  - 6.2.4.1.1 Key market trends, growth factors and opportunities
  - 6.2.4.1.2 Market size and forecast, by Drug Type
  - 6.2.4.1.3 Market size and forecast, by Distribution Channel
  - 6.2.4.2 Canada
  - 6.2.4.2.1 Key market trends, growth factors and opportunities
  - 6.2.4.2.2 Market size and forecast, by Drug Type
  - 6.2.4.2.3 Market size and forecast, by Distribution Channel
  - 6.2.4.3 Mexico
  - 6.2.4.3.1 Key market trends, growth factors and opportunities
  - 6.2.4.3.2 Market size and forecast, by Drug Type
  - 6.2.4.3.3 Market size and forecast, by Distribution Channel
6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Drug Type
- 6.3.3 Europe Market size and forecast, by Distribution Channel
- 6.3.4 Europe Market size and forecast, by country
  - 6.3.4.1 Germany
  - 6.3.4.1.1 Key market trends, growth factors and opportunities
  - 6.3.4.1.2 Market size and forecast, by Drug Type
  - 6.3.4.1.3 Market size and forecast, by Distribution Channel
  - 6.3.4.2 France
  - 6.3.4.2.1 Key market trends, growth factors and opportunities
  - 6.3.4.2.2 Market size and forecast, by Drug Type
  - 6.3.4.2.3 Market size and forecast, by Distribution Channel
  - 6.3.4.3 UK
  - 6.3.4.3.1 Key market trends, growth factors and opportunities
  - 6.3.4.3.2 Market size and forecast, by Drug Type
  - 6.3.4.3.3 Market size and forecast, by Distribution Channel
  - 6.3.4.4 Italy
  - 6.3.4.4.1 Key market trends, growth factors and opportunities
  - 6.3.4.4.2 Market size and forecast, by Drug Type
  - 6.3.4.4.3 Market size and forecast, by Distribution Channel
  - 6.3.4.5 Spain
  - 6.3.4.5.1 Key market trends, growth factors and opportunities
  - 6.3.4.5.2 Market size and forecast, by Drug Type
  - 6.3.4.5.3 Market size and forecast, by Distribution Channel
  - 6.3.4.6 Rest of Europe
  - 6.3.4.6.1 Key market trends, growth factors and opportunities
  - 6.3.4.6.2 Market size and forecast, by Drug Type
  - 6.3.4.6.3 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Drug Type
- 6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
- 6.4.4 Asia-Pacific Market size and forecast, by country
  - 6.4.4.1 China
  - 6.4.4.1.1 Key market trends, growth factors and opportunities
  - 6.4.4.1.2 Market size and forecast, by Drug Type
  - 6.4.4.1.3 Market size and forecast, by Distribution Channel
  - 6.4.4.2 Japan
  - 6.4.4.2.1 Key market trends, growth factors and opportunities
  - 6.4.4.2.2 Market size and forecast, by Drug Type
  - 6.4.4.2.3 Market size and forecast, by Distribution Channel
  - 6.4.4.3 India
  - 6.4.4.3.1 Key market trends, growth factors and opportunities
  - 6.4.4.3.2 Market size and forecast, by Drug Type
  - 6.4.4.3.3 Market size and forecast, by Distribution Channel
  - 6.4.4.4 South Korea
  - 6.4.4.4.1 Key market trends, growth factors and opportunities
  - 6.4.4.4.2 Market size and forecast, by Drug Type
  - 6.4.4.4.3 Market size and forecast, by Distribution Channel
  - 6.4.4.5 Australia
  - 6.4.4.5.1 Key market trends, growth factors and opportunities
  - 6.4.4.5.2 Market size and forecast, by Drug Type
  - 6.4.4.5.3 Market size and forecast, by Distribution Channel
  - 6.4.4.6 Rest of Asia-Pacific
  - 6.4.4.6.1 Key market trends, growth factors and opportunities
  - 6.4.4.6.2 Market size and forecast, by Drug Type
  - 6.4.4.6.3 Market size and forecast, by Distribution Channel
6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Drug Type
- 6.5.3 LAMEA Market size and forecast, by Distribution Channel
- 6.5.4 LAMEA Market size and forecast, by country
  - 6.5.4.1 Brazil
  - 6.5.4.1.1 Key market trends, growth factors and opportunities
  - 6.5.4.1.2 Market size and forecast, by Drug Type
  - 6.5.4.1.3 Market size and forecast, by Distribution Channel
  - 6.5.4.2 Saudi Arabia
  - 6.5.4.2.1 Key market trends, growth factors and opportunities
  - 6.5.4.2.2 Market size and forecast, by Drug Type
  - 6.5.4.2.3 Market size and forecast, by Distribution Channel
  - 6.5.4.3 South Africa
  - 6.5.4.3.1 Key market trends, growth factors and opportunities
  - 6.5.4.3.2 Market size and forecast, by Drug Type
  - 6.5.4.3.3 Market size and forecast, by Distribution Channel
  - 6.5.4.4 Rest of LAMEA
  - 6.5.4.4.1 Key market trends, growth factors and opportunities
  - 6.5.4.4.2 Market size and forecast, by Drug Type
  - 6.5.4.4.3 Market size and forecast, by Distribution Channel

CHAPTER 7: COMPANY LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.5. Top player positioning, 2021

CHAPTER 8: COMPANY PROFILES

8.1 Apotex
- 8.1.1 Company overview
- 8.1.2 Key Executives
- 8.1.3 Company snapshot
- 8.1.4 Operating business segments
- 8.1.5 Product portfolio
- 8.1.6 Business performance
- 8.1.7 Key strategic moves and developments
8.2 ANI Pharmaceuticals Inc
- 8.2.1 Company overview
- 8.2.2 Key Executives
- 8.2.3 Company snapshot
- 8.2.4 Operating business segments
- 8.2.5 Product portfolio
- 8.2.6 Business performance
- 8.2.7 Key strategic moves and developments
8.3 Teva Pharmaceutical Industries Limited
- 8.3.1 Company overview
- 8.3.2 Key Executives
- 8.3.3 Company snapshot
- 8.3.4 Operating business segments
- 8.3.5 Product portfolio
- 8.3.6 Business performance
- 8.3.7 Key strategic moves and developments
8.4 Lupin Ltd
- 8.4.1 Company overview
- 8.4.2 Key Executives
- 8.4.3 Company snapshot
- 8.4.4 Operating business segments
- 8.4.5 Product portfolio
- 8.4.6 Business performance
- 8.4.7 Key strategic moves and developments
8.5 Dr.Reddy's Laboratories Ltd
- 8.5.1 Company overview
- 8.5.2 Key Executives
- 8.5.3 Company snapshot
- 8.5.4 Operating business segments
- 8.5.5 Product portfolio
- 8.5.6 Business performance
- 8.5.7 Key strategic moves and developments
8.6 Bausch Health Companies Inc.
- 8.6.1 Company overview
- 8.6.2 Key Executives
- 8.6.3 Company snapshot
- 8.6.4 Operating business segments
- 8.6.5 Product portfolio
- 8.6.6 Business performance
- 8.6.7 Key strategic moves and developments
8.7 Panacea Biotec Ltd
- 8.7.1 Company overview
- 8.7.2 Key Executives
- 8.7.3 Company snapshot
- 8.7.4 Operating business segments
- 8.7.5 Product portfolio
- 8.7.6 Business performance
- 8.7.7 Key strategic moves and developments
8.8 par pharmaceutical
- 8.8.1 Company overview
- 8.8.2 Key Executives
- 8.8.3 Company snapshot
- 8.8.4 Operating business segments
- 8.8.5 Product portfolio
- 8.8.6 Business performance
- 8.8.7 Key strategic moves and developments
8.9 navinta llc
- 8.9.1 Company overview
- 8.9.2 Key Executives
- 8.9.3 Company snapshot
- 8.9.4 Operating business segments
- 8.9.5 Product portfolio
- 8.9.6 Business performance
- 8.9.7 Key strategic moves and developments
8.10 breckenridge pharmaceutical, inc.
- 8.10.1 Company overview
- 8.10.2 Key Executives
- 8.10.3 Company snapshot
- 8.10.4 Operating business segments
- 8.10.5 Product portfolio
- 8.10.6 Business performance
- 8.10.7 Key strategic moves and developments